Aymeric Ravel-Chapuis
Overview
Explore the profile of Aymeric Ravel-Chapuis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
415
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ravel-Chapuis A, Fahmi C, Gobin J, Jasmin B
FASEB J
. 2024 Nov;
38(23):e70199.
PMID: 39611312
Multiple signaling pathways have been reported to be altered in Myotonic Dystrophy type 1 (DM1) skeletal muscle, contributing to pathogenicity. In particular, previous work established that AMPK signaling, a key...
2.
Roussel M, Ravel-Chapuis A, Gobin J, Jasmin B, Leduc-Gaudet J, Gagnon C, et al.
J Neuromuscul Dis
. 2024 Jul;
11(5):981-995.
PMID: 39031377
Background: Myotonic dystrophy type 1 (DM1) is a slowly progressive disease caused by abnormal CTG repetitions on the dystrophia myotonica protein kinase (DMPK) gene. Long mRNA from CTG repetitions stabilizes...
3.
Neault N, Ravel-Chapuis A, Baird S, Lunde J, Poirier M, Staykov E, et al.
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36835205
Myotonic dystrophy type 1 (DM1), the most common form of adult muscular dystrophy, is caused by an abnormal expansion of CTG repeats in the 3' untranslated region of the dystrophia...
4.
Osseni A, Ravel-Chapuis A, Belotti E, Scionti I, Gangloff Y, Moncollin V, et al.
Nat Commun
. 2022 Nov;
13(1):7108.
PMID: 36402791
The absence of dystrophin in Duchenne muscular dystrophy disrupts the dystrophin-associated glycoprotein complex resulting in skeletal muscle fiber fragility and atrophy, associated with fibrosis as well as microtubule and neuromuscular...
5.
Misquitta N, Ravel-Chapuis A, Jasmin B
Hum Mol Genet
. 2022 Sep;
32(4):551-566.
PMID: 36048859
Targeting AMP-activated protein kinase (AMPK) is emerging as a promising strategy for treating myotonic dystrophy type 1 (DM1), the most prevalent form of adult-onset muscular dystrophy. We previously demonstrated that...
6.
Freeman E, Langlois S, Scott K, Ravel-Chapuis A, Jasmin B, Cowan K
J Cell Physiol
. 2022 Aug;
237(10):3944-3959.
PMID: 35938715
The development and regeneration of skeletal muscle are mediated by satellite cells (SCs), which ensure the efficient formation of myofibers while repopulating the niche that allows muscle repair following injuries....
7.
Ravel-Chapuis A, Duchesne E, Jasmin B
J Physiol
. 2022 Jun;
600(14):3249-3264.
PMID: 35695045
Myotonic dystrophy type 1 (DM1) is a multisystemic disorder with variable clinical features. Currently, there is no cure or effective treatment for DM1. The disease is caused by an expansion...
8.
Ravel-Chapuis A, Jasmin B
Trends Mol Med
. 2022 May;
28(6):439-442.
PMID: 35537989
Myotonic dystrophy type 1 (DM1) is a multisystemic disorder for which there is no cure. In recent years, progress has been made in defining disease mechanisms and in developing novel...
9.
Ravel-Chapuis A, Haghandish A, Daneshvar N, Jasmin B, Cote J
Hum Mol Genet
. 2021 Nov;
31(9):1453-1470.
PMID: 34791230
Spinal muscular atrophy (SMA) is characterized by the loss of alpha motor neurons in the spinal cord and a progressive muscle weakness and atrophy. SMA is caused by loss-of-function mutations...
10.
Almasi S, Crawford Parks T, Ravel-Chapuis A, Mackenzie A, Cote J, Cowan K, et al.
Cell Oncol (Dordr)
. 2021 Apr;
44(4):851-870.
PMID: 33899158
Purpose: Recent work has highlighted the therapeutic potential of targeting autophagy to modulate cell survival in a variety of diseases including cancer. Recently, we found that the RNA-binding protein Staufen1...